Andrew Mulato
Overview
Explore the profile of Andrew Mulato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mulato A, Lansdon E, Aoyama R, Voigt J, Lee M, Liclican A, et al.
Antimicrob Agents Chemother
. 2024 Feb;
68(4):e0137323.
PMID: 38380945
Protease inhibitors (PIs) remain an important component of antiretroviral therapy for the treatment of HIV-1 infection due to their high genetic barrier to resistance development. Nevertheless, the two most commonly...
2.
Subramanian R, Tang J, Zheng J, Lu B, Wang K, Yant S, et al.
Mol Pharm
. 2023 Nov;
20(12):6213-6225.
PMID: 37917742
Lenacapavir (LEN) is a picomolar first-in-class capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) with a multistage mechanism of action and no known cross resistance to other existing antiretroviral...
3.
Acosta R, DAntoni M, Mulato A, Yant S, Cihlar T, White K
Antimicrob Agents Chemother
. 2022 Apr;
66(5):e0203821.
PMID: 35389236
The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected patients, with various limitations. Here, time...
4.
Mulato A, Acosta R, Chang S, Martin R, Yant S, Cihlar T, et al.
J Acquir Immune Defic Syndr
. 2020 Nov;
86(3):369-377.
PMID: 33196554
Background: Barriers to lifelong HIV-1 suppression by antiretrovirals include poor adherence and drug resistance; regimens with higher tolerance to missed doses (forgiveness) would be beneficial to patients. To model short-term...
5.
Link J, Rhee M, Tse W, Zheng J, Somoza J, Rowe W, et al.
Nature
. 2020 Jul;
584(7822):614-618.
PMID: 32612233
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis. However, some people living with HIV who are heavily...
6.
Yant S, Mulato A, Hansen D, Tse W, Niedziela-Majka A, Zhang J, et al.
Nat Med
. 2019 Sep;
25(9):1377-1384.
PMID: 31501601
People living with HIV (PLWH) have expressed concern about the life-long burden and stigma associated with taking pills daily and can experience medication fatigue that might lead to suboptimal treatment...
7.
Pohlmeyer C, Gonzalez V, Irrinki A, Ramirez R, Li L, Mulato A, et al.
J Virol
. 2019 Feb;
93(7).
PMID: 30700608
HIV infection is controlled immunologically in a small subset of infected individuals without antiretroviral therapy (ART), though the mechanism of control is unclear. CD8 T cells are a critical component...
8.
Bam R, Hansen D, Irrinki A, Mulato A, Jones G, Hesselgesser J, et al.
Antimicrob Agents Chemother
. 2016 Nov;
61(1).
PMID: 27799218
GS-9620 is a potent and selective oral Toll-like receptor 7 (TLR7) agonist that directly activates plasmacytoid dendritic cells (pDCs). GS-9620 suppressed hepatitis B virus (HBV) in animal models of chronic...
9.
Tsiang M, Jones G, Goldsmith J, Mulato A, Hansen D, Kan E, et al.
Antimicrob Agents Chemother
. 2016 Sep;
60(12):7086-7097.
PMID: 27645238
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC] of 7.5 ± 0.3 nM) and HIV-1...
10.
Mulato A, Hansen D, Thielen A, Porter D, Stepan G, White K, et al.
AIDS Res Hum Retroviruses
. 2016 Jul;
32(12):1237-1247.
PMID: 27356854
Failure of combination antiretroviral (ARV) therapy in HIV-infected patients is often associated with the emergence of drug resistance-associated mutations (RAMs). To facilitate analysis of the barrier to resistance at therapeutically...